Consumers Union, Consumer Federation of America, U.S. PIRG, Public Citizen, Consumer Action, Consumer Watchdog, Community Catalyst, and National Center for Health Research, have had a growing concern in recent years as the generic drug industry has become increasingly concentrated. The latest announced merger — the hostile bid by Teva Pharmaceuticals (“Teva”) to acquire Mylan — would combine the two largest generic drug manufacturers in the United States. This letter to the Federal Trade Commission expresses a concern that this merger would: (1) increase prices for generic as well as specialty drugs; (2) exacerbate drug shortages; and (3) reduce the development of new generic drugs. The organizations urge the Federal Trade Commission to investigate this merger thoroughly, and to take action to block it.